Expand / Collapse search
Watch TV
☰

Quotes displayed in real-time or delayed by at least 15 minutes. Market data provided by Factset. Powered and implemented by FactSet Digital Solutions.  Legal Statement.

This material may not be published, broadcast, rewritten, or redistributed. ©2026 FOX News Network, LLC. All rights reserved. FAQ - New Privacy Policy

artivion inc. - AORT

AORT

Close Chg Chg %
21.04 -0.62 -2.92%

Closed Market

20.43

-0.62 (2.92%)

Volume: 662.09K

Last Updated:

Jun 2, 2026, 3:59 PM EDT

Trade Now

Company Overview: artivion inc. - AORT

AORT Key Data

Open

$20.99

 Day Range

20.39 - 20.99

52 Week Range

19.16 - 48.25

 Market Cap

$1.02B

Shares Outstanding

48.54M

 Public Float

46.09M

Beta

1.25

 Rev. Per Employee

N/A

P/E Ratio

87.67

 EPS

$0.25

Yield

0.00%

 Dividend

$0.03

EX-DIVIDEND DATE

Dec 9, 2015

 SHORT INTEREST

N/A

AVERAGE VOLUME

944.56K

  

AORT Performance

1 Week
 
 -7.98%
 
1 Month
 
 -43.61%
 
3 Months
 
 -44.87%
 
1 Year
 
 -29.46%
 
5 Years
 
 -29.32%
 

AORT Analyst Ratings

  • Sell
  • Under
  • Hold
  • Over
  • Buy
Number of Ratings 8
Full Ratings ➔

About artivion inc. - AORT

Artivion, Inc. engages in the manufacture, processing, and distribution of medical devices and implantable human tissues used in cardiac and vascular surgical procedures for patients with aortic disease. It operates through the Medical Devices and Preservation Services segments. The Medical Devices segment includes aortic stents and stent grafts, surgical sealants, and On-X products. The Preservation Services segment offers cardiac and vascular tissue preservation services. The company was founded on January 19, 1984, and is headquartered in Kennesaw, GA.

AORT At a Glance

Artivion, Inc.
1655 Roberts Boulevard NW
Kennesaw, Georgia 30144-3632
Phone 1-770-419-3355 Revenue 441.33M
Industry Medical Specialties Net Income 9.76M
Sector Health Technology 2025 Sales Growth 13.588%
Fiscal Year-end 12 / 2026 Employees 1,800
View SEC Filings

AORT Valuation

P/E Current 87.672
P/E Ratio (with extraordinary items) N/A
P/E Ratio (without extraordinary items) 220.445
Price to Sales Ratio 4.874
Price to Book Ratio 4.868
Price to Cash Flow Ratio 53.94
Enterprise Value to EBITDA 41.394
Enterprise Value to Sales 5.313
Total Debt to Enterprise Value 0.11

AORT Efficiency

Revenue/Employee 245,183.333
Income Per Employee 5,420.556
Receivables Turnover 4.257
Total Asset Turnover 0.527

AORT Liquidity

Current Ratio 2.989
Quick Ratio 2.079
Cash Ratio 0.639

AORT Profitability

Gross Margin 61.281
Operating Margin 7.746
Pretax Margin 3.349
Net Margin 2.211
Return on Assets 1.166
Return on Equity 2.694
Return on Total Capital 1.381
Return on Invested Capital 1.463

AORT Capital Structure

Total Debt to Total Equity 57.674
Total Debt to Total Capital 36.578
Total Debt to Total Assets 29.217
Long-Term Debt to Equity 56.274
Long-Term Debt to Total Capital 35.69
  • Income Statement
  • Balance Sheet
  • Cash Flow Statement

Annual Financials for Artivion Inc. - AORT

Collapse All in section
All values USD millions. 2022 2023 2024 2025 5-year trend
Sales/Revenue
313.79M 354.00M 388.54M 441.33M
Sales Growth
+5.00% +12.82% +9.75% +13.59%
Cost of Goods Sold (COGS) incl D&A
126.58M 140.03M 155.61M 170.88M
COGS excluding D&A
- - - -
-
Depreciation & Amortization Expense
22.44M 23.08M 24.20M 22.46M
Depreciation
7.13M 7.88M 8.35M 8.68M
Amortization of Intangibles
15.31M 15.20M 15.86M 13.78M
COGS Growth
+7.14% +10.63% +11.13% +9.81%
Gross Income
187.21M 213.98M 232.93M 270.45M
Gross Income Growth
+3.61% +14.30% +8.86% +16.11%
Gross Profit Margin
+59.66% +60.45% +59.95% +61.28%
2022 2023 2024 2025 5-year trend
SG&A Expense
172.23M 199.19M 205.44M 236.27M
Research & Development
38.88M 28.71M 28.45M 30.99M
Other SG&A
133.35M 170.48M 176.99M 205.28M
SGA Growth
-1.21% +15.65% +3.14% +15.01%
Other Operating Expense
- - - -
-
Unusual Expense
9.47M 28.88M (2.44M) 12.66M
EBIT after Unusual Expense
5.51M (14.09M) 29.93M 21.52M
Non Operating Income/Expense
(2.65M) 17.89M (3.08M) 19.93M
Non-Operating Interest Income
147.00K 1.08M 1.47M 763.00K
Equity in Earnings of Affiliates
- - - -
-
Interest Expense
17.84M 25.38M 34.37M 26.68M
Interest Expense Growth
+7.96% +42.29% +35.39% -22.38%
Gross Interest Expense
17.84M 25.38M 34.37M 26.68M
Interest Capitalized
- - - -
-
Pretax Income
(14.98M) (21.59M) (7.51M) 14.78M
Pretax Income Growth
-1.06% -44.06% +65.19% +296.70%
Pretax Margin
-4.78% -6.10% -1.93% +3.35%
Income Tax
4.21M 9.10M 5.84M 5.01M
Income Tax - Current - Domestic
1.97M 6.58M 6.69M 1.16M
Income Tax - Current - Foreign
3.12M 3.85M 665.00K 3.82M
Income Tax - Deferred - Domestic
470.00K 379.00K 815.00K 396.00K
Income Tax - Deferred - Foreign
(1.35M) (1.70M) (2.33M) (359.00K)
Income Tax Credits
- - - -
-
Equity in Earnings of Affiliates
- - - -
-
Other After Tax Income (Expense)
98.00K 123.00K 24.00K (11.00K)
Consolidated Net Income
(19.09M) (30.57M) (13.34M) 9.76M
Minority Interest Expense
- - - -
-
Net Income
(19.09M) (30.57M) (13.34M) 9.76M
Net Income Growth
-29.54% -60.09% +56.37% +173.17%
Net Margin Growth
-6.08% -8.63% -3.43% +2.21%
Extraordinaries & Discontinued Operations
- - - -
-
Discontinued Operations
- - - -
-
Net Income After Extraordinaries
(19.09M) (30.57M) (13.34M) 9.76M
Preferred Dividends
- - - -
-
Net Income Available to Common
(19.09M) (30.57M) (13.34M) 9.76M
EPS (Basic)
-0.477 -0.7502 -0.32 0.2152
EPS (Basic) Growth
-26.16% -57.27% +57.34% +167.25%
Basic Shares Outstanding
40.03M 40.74M 41.68M 45.34M
EPS (Diluted)
-0.477 -0.7502 -0.32 0.2069
EPS (Diluted) Growth
-26.16% -57.27% +57.34% +164.66%
Diluted Shares Outstanding
40.03M 40.74M 41.68M 47.16M
EBITDA
37.43M 37.86M 51.69M 56.64M
EBITDA Growth
+23.41% +1.17% +36.52% +9.58%
EBITDA Margin
+11.93% +10.70% +13.30% +12.83%

Snapshot

Average Recommendation BUY Average Target Price 42.875
Number of Ratings 8 Current Quarters Estimate 0.019
FY Report Date 06 / 2026 Current Year's Estimate 0.141
Last Quarter’s Earnings 0.03 Median PE on CY Estimate N/A
Year Ago Earnings 0.21 Next Fiscal Year Estimate 0.451
Median PE on Next FY Estimate N/A

Earnings Per Share

This Quarter Next Quarter This Fiscal Next Fiscal
# of Estimates 8 8 8 8
Mean Estimate 0.02 0.02 0.14 0.45
High Estimates 0.07 0.07 0.29 0.70
Low Estimate -0.03 -0.08 -0.12 0.13
Coefficient of Variance 172.09 297.31 94.64 37.78

Analysts Recommendations

Current 1 Month Ago 3 Months Ago
BUY 8 8 6
OVERWEIGHT 0 0 0
HOLD 0 0 1
UNDERWEIGHT 0 0 0
SELL 0 0 0
MEAN Buy Buy Buy

Insider Actions for Artivion Inc. - AORT

Date Name Shares Transaction Value
Mar 4, 2026 Jean F. Holloway SVP, General Counsel 170,105 Open market or private sale of non-derivative or derivative security Non-derivative transaction at $38.02 per share 6,467,392.10
Mar 4, 2026 Lance A. Berry EVP, COO, CFO & Treasurer 176,269 Open market or private sale of non-derivative or derivative security Non-derivative transaction at $38.02 per share 6,701,747.38
Mar 4, 2026 Amy D. Horton VP, Chief Accounting Officer 132,514 Open market or private sale of non-derivative or derivative security Non-derivative transaction at $38.02 per share 5,038,182.28
Mar 4, 2026 Marshall S. Stanton SVP, Clinical & MD Affair 40,408 Open market or private sale of non-derivative or derivative security Non-derivative transaction at $38.02 per share 1,536,312.16
Mar 4, 2026 James Patrick Mackin President & CEO 848,214 Open market or private sale of non-derivative or derivative security Non-derivative transaction at $38.02 per share 32,249,096.28
Mar 4, 2026 John Elery Davis Chief Commercial Officer 206,522 Open market or private sale of non-derivative or derivative security Non-derivative transaction at $38.02 per share 7,851,966.44
Jan 29, 2026 Jean F. Holloway SVP, General Counsel 156,950 Grant, award or other acq pursuant to Rule 16b-3(d) Non-derivative transaction at $26.14 per share 4,102,673.00
Jan 29, 2026 Marshall S. Stanton SVP, Clinical & MD Affair 45,603 Grant, award or other acq pursuant to Rule 16b-3(d) Non-derivative transaction at $26.14 per share 1,192,062.42
Aug 15, 2025 Jean F. Holloway SVP, General Counsel 172,129 Open market or private sale of non-derivative or derivative security Non-derivative transaction at $43.02 per share 7,404,989.58
Aug 15, 2025 Jean F. Holloway SVP, General Counsel N/A Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 0.00

Artivion Inc. in the News